Pressure BioSciences (OTCMKTS:PBIO) CEO Richard Schumacher tells Proactive Investors the life science group reported a jump in first-quarter revenue thanks to an uptick in instrument sales, and said the company has shrunk its debt.
Schumacher says the company is very proud of their progress, having done $2.2mln in sales in 2017. He says the company has hired more sales staff, and touted a new pressure chamber instrument that allows for a number of “bells and whistles” for researchers.
Click on the link below to watch the full interview:
About Pressure BioSciences, Inc.
Pressure BioSciences, Inc. (OTCQB: PBIO) is a leader in the development and sale of innovative, broadly enabling, pressure-based solutions for the worldwide life sciences industry. Our products are based on the unique properties of both constant (i.e., static) and alternating (i.e., pressure cycling technology, or “PCT”) hydrostatic pressure. PCT is a patented enabling technology platform that uses alternating cycles of hydrostatic pressure between ambient and ultra-high levels to safely and reproducibly control biomolecular interactions (e.g., cell lysis, biomolecule extraction). Our primary focus is in the development of PCT-based products for biomarker and target discovery, drug design and development, biotherapeutics characterization and quality control, soil & plant biology, forensics, and counter-bioterror applications. Additionally, major new market opportunities have emerged in the use of our pressure-based technologies in the following areas: (1) the use of our recently acquired PreEMT technology from BaroFold, Inc. to allow immediate entry into the biologics contract research services sector, and (2) the use of our recently patented, scalable, high-efficiency, pressure-based Ultra Shear Technology (“UST”) platform to (i) create stable nanoemulsions of otherwise immiscible fluids (e.g., oils and water) and to (ii) prepare higher quality, homogenized, extended shelf-life or room temperature stable low-acid liquid foods that cannot be effectively preserved using existing non-thermal technologies.
For more information about PBI and this press release, please click on the following link: http://www.pressurebiosciences.com
Please visit us on Facebook, LinkedIn, and Twitter.